Alnylam

Alnylam
Focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
RNA Interference
Gene Therapy
Drug Development
Biomedical Research
Open roles at Alnylam
0 open roles
No open positions at this time
Products and services
ON
ONPATTRO (patisiran)
Marketed Drug
RN
RNAi Platform Technology
Technology Platform
AM
AMVUTTRA (vutrisiran)
Marketed Drug
OX
OXLUMO (lumasiran)
Marketed Drug
GI
GIVLAARI (givosiran)
Marketed Drug

Drug Development Services
Services
CE
Cemdisiran
Pipeline Drug
LE
LEQVIO (inclisiran)
Partnered Drug
AL
ALN-APP
Pipeline Drug

Fitusiran
Pipeline Drug
AL
ALN-HBV02
Pipeline Drug
Latest updates
All
X
News
HN
YouTube
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
MSN
News
·
1 month ago
Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial - Yahoo Finance
Yahoo Finance
News
·
1 month ago
Seagate, Alnylam among six companies set to join Nasdaq 100 - MSN
MSN
News
·
1 month ago
Acrylamide
HN
·
1 month ago
·
2
·
1
Bernstein SocGen cuts Alnylam stock price target on Amvuttra focus - Investing.com
Investing.com
News
·
1 month ago
Show 15 more
Total Views
0
Total Apply Clicks
0
Total Mock Apply
0
Total Bookmarks
0
Reviews
4.1
10 reviews
Work-life balance
2.8
Compensation
4.2
Culture
4.0
Career
3.5
Management
3.2
75%
Recommend to a friend
Pros
Great benefits and health benefits
Collaborative team environment
Cutting-edge research and challenging projects
Cons
High workload and overwhelming demands
Work-life balance issues
Limited career advancement opportunities
Salary Ranges
69 data points
Director
Intern
Mid/L4
Senior/L5
Director
1 reports
$231,400
total per year
Base
$178,000
Stock
-
$231,400
$231,400
Interview experience
3 interviews
Difficulty
3.0
/ 5
Duration
2-5w
Experience
Positive 0%
Neutral 33%
Negative 67%
Interview process
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Final Round Interview
6
Offer
Contact and location